Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 in Relapsed or Refractory Classical Hodgkin's Lymphoma
NCT03800706Phase 2Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Mar 2019
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of benmelstobart in classical Hodgkin lymphoma (cHL), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Overall Response Rate up to 96 weeks. Status: unknown.
02
Drugs
benmelstobart
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT03800706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03800706.